RxSight Stock Still Seen with Upside After Revised Guidance Appears Conservative -- Market Talk

Dow Jones

Jul 09, 2025

09:12 ET -- RxSight is likely in the penalty box over the near-term following Tuesday's results and guidance, but Needham analysts maintain their buy rating. The ophthalmic medical device company on Tuesday guided for a decline in 2Q revenue and lowered its full-year revenue guidance. "We believe the new guidance bakes in areas of conservatism," say the analysts. "Further, we believe expansion of its U.S. commercial pivot and recent OUS launches could become areas of growth over the next 12-18 months." They also believe the valuation gap between RxSight and two of its peers could close over time, making the risk/reward over the next 12 months to skew positive, leading to their maintained rating. Shares dive 49% to $6.50 in premarket trading. (denny.jacob@wsj.com; @pennedbyden)

(END) Dow Jones Newswires

July 09, 2025 09:12 ET (13:12 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2550583146"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2550583146\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2550583146?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-09 21:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2550583146","market":"fut","top_or_hot":-1,"title":"RxSight Stock Still Seen with Upside After Revised Guidance Appears Conservative -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  09:12 ET -- RxSight is likely in the penalty box over the near-term following Tuesday's results and guidance, but Needham analysts maintain their buy rating. The ophthalmic medical device company on Tuesday guided for a decline in 2Q revenue and lowered its full-year revenue guidance. \"We believe the new guidance bakes in areas of conservatism,\" say the analysts. \"Further, we believe expansion of its U.S. commercial pivot and recent OUS launches could become areas of growth over the next 12-18 months.\" They also believe the valuation gap between RxSight and two of its peers could close over time, making the risk/reward over the next 12 months to skew positive, leading to their maintained rating. Shares dive 49% to $6.50 in premarket trading. (denny.jacob@wsj.com; @pennedbyden) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 09, 2025 09:12 ET (13:12 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RxSight Stock Still Seen with Upside After Revised Guidance Appears Conservative -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRxSight Stock Still Seen with Upside After Revised Guidance Appears Conservative -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-07-09 21:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  09:12 ET -- RxSight is likely in the penalty box over the near-term following Tuesday's results and guidance, but Needham analysts maintain their buy rating. The ophthalmic medical device company on Tuesday guided for a decline in 2Q revenue and lowered its full-year revenue guidance. \"We believe the new guidance bakes in areas of conservatism,\" say the analysts. \"Further, we believe expansion of its U.S. commercial pivot and recent OUS launches could become areas of growth over the next 12-18 months.\" They also believe the valuation gap between RxSight and two of its peers could close over time, making the risk/reward over the next 12 months to skew positive, leading to their maintained rating. Shares dive 49% to $6.50 in premarket trading. (denny.jacob@wsj.com; @pennedbyden) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 09, 2025 09:12 ET (13:12 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4198","symbol_name":"医疗保健用品","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2550583146","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2550583146","pubTimestamp":1752066720,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"09:12 ET -- RxSight is likely in the penalty box over the near-term following Tuesday's results and guidance, but Needham analysts maintain their buy rating. The ophthalmic medical device company on Tuesday guided for a decline in 2Q revenue and lowered its full-year revenue guidance. \"We believe the new guidance bakes in areas of conservatism,\" say the analysts. \"Further, we believe expansion of its U.S. commercial pivot and recent OUS launches could become areas of growth over the next 12-18 months.\" They also believe the valuation gap between RxSight and two of its peers could close over time, making the risk/reward over the next 12 months to skew positive, leading to their maintained rating. Shares dive 49% to $6.50 in premarket trading. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4198":"医疗保健用品","BK4539":"次新股","RXST":"RxSIGHT, INC."},"translate_title":"在修订后的指引显得保守后，RxSight股票仍有上涨空间——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RXST":0.9},"content_text":"09:12 ET -- RxSight is likely in the penalty box over the near-term following Tuesday's results and guidance, but Needham analysts maintain their buy rating. The ophthalmic medical device company on Tuesday guided for a decline in 2Q revenue and lowered its full-year revenue guidance. \"We believe the new guidance bakes in areas of conservatism,\" say the analysts. \"Further, we believe expansion of its U.S. commercial pivot and recent OUS launches could become areas of growth over the next 12-18 months.\" They also believe the valuation gap between RxSight and two of its peers could close over time, making the risk/reward over the next 12 months to skew positive, leading to their maintained rating. Shares dive 49% to $6.50 in premarket trading. (denny.jacob@wsj.com; @pennedbyden) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 09, 2025 09:12 ET (13:12 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}